| Literature DB >> 28191885 |
Chen-Hua Chuang1, Peyton G Greenside2, Zoë N Rogers1, Jennifer J Brady1, Dian Yang3, Rosanna K Ma1, Deborah R Caswell3, Shin-Heng Chiou1, Aidan F Winters1, Barbara M Grüner1, Gokul Ramaswami1, Andrew L Spencley3, Kimberly E Kopecky4, Leanne C Sayles5, E Alejandro Sweet-Cordero3,5, Jin Billy Li1, Anshul Kundaje1,6, Monte M Winslow1,3,7.
Abstract
Lung cancer is the leading cause of cancer deaths worldwide, with the majority of mortality resulting from metastatic spread. However, the molecular mechanism by which cancer cells acquire the ability to disseminate from primary tumors, seed distant organs, and grow into tissue-destructive metastases remains incompletely understood. We combined tumor barcoding in a mouse model of human lung adenocarcinoma with unbiased genomic approaches to identify a transcriptional program that confers metastatic ability and predicts patient survival. Small-scale in vivo screening identified several genes, including Cd109, that encode novel pro-metastatic factors. We uncovered signaling mediated by Janus kinases (Jaks) and the transcription factor Stat3 as a critical, pharmacologically targetable effector of CD109-driven lung cancer metastasis. In summary, by coupling the systematic genomic analysis of purified cancer cells in distinct malignant states from mouse models with extensive human validation, we uncovered several key regulators of metastatic ability, including an actionable pro-metastatic CD109-Jak-Stat3 axis.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28191885 PMCID: PMC6453542 DOI: 10.1038/nm.4285
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440